NL7605382A
(nl)
*
|
1975-06-04 |
1976-12-07 |
Sumitomo Chemical Co |
Werkwijze voor het bereiden van indoolderivaten.
|
JPS5328173A
(en)
*
|
1976-08-06 |
1978-03-16 |
Zenyaku Kogyo Kk |
Novel phenylmethanenitro compound and its preparation
|
DE2735133C2
(de)
|
1977-08-04 |
1981-10-15 |
Universität Karlsruhe Institut für Elektrotechnische Grundlagen der Informatik, 7500 Karlsruhe |
Speicherzelle für zerstörungsfreies Auslesen mit 2 Josephson-Kontakten
|
US4138397A
(en)
|
1978-02-27 |
1979-02-06 |
Richardson-Merrell Inc. |
6-(2,3-Dihydro-5-benzofuranyl)acetamido penicillin derivatives
|
GB8524157D0
(en)
|
1984-10-19 |
1985-11-06 |
Ici America Inc |
Heterocyclic amides
|
JPS61103861A
(ja)
*
|
1984-10-27 |
1986-05-22 |
Nitto Kasei Kk |
アリ−ル置換シアン酢酸エステルの製造方法
|
US5304121A
(en)
|
1990-12-28 |
1994-04-19 |
Boston Scientific Corporation |
Drug delivery system making use of a hydrogel polymer coating
|
US5886026A
(en)
|
1993-07-19 |
1999-03-23 |
Angiotech Pharmaceuticals Inc. |
Anti-angiogenic compositions and methods of use
|
GB9317764D0
(en)
|
1993-08-26 |
1993-10-13 |
Pfizer Ltd |
Therapeutic compound
|
US5510379A
(en)
|
1994-12-19 |
1996-04-23 |
Warner-Lambert Company |
Sulfonate ACAT inhibitors
|
US6099562A
(en)
|
1996-06-13 |
2000-08-08 |
Schneider (Usa) Inc. |
Drug coating with topcoat
|
JPH10213820A
(ja)
|
1997-01-31 |
1998-08-11 |
Canon Inc |
液晶素子及び液晶装置
|
WO1998047868A1
(en)
|
1997-04-18 |
1998-10-29 |
Smithkline Beecham Plc |
Heterocycle-containing urea derivatives as 5ht1a, 5ht1b and 5ht1d receptor antagonists
|
DE69831233T2
(de)
*
|
1997-06-21 |
2006-06-01 |
Roche Diagnostics Gmbh |
Barbitursaure derivaten mit antimetastatischer und antitumorischer wirkung
|
DK0901786T3
(da)
|
1997-08-11 |
2007-10-08 |
Pfizer Prod Inc |
Faste farmaceutiske dispersioner med foröget biotilgængelighed
|
US20020017295A1
(en)
|
2000-07-07 |
2002-02-14 |
Weers Jeffry G. |
Phospholipid-based powders for inhalation
|
ATE249219T1
(de)
|
1997-12-11 |
2003-09-15 |
Iaf Biochem Int |
Antivirale verbindungen
|
US6426331B1
(en)
|
1998-07-08 |
2002-07-30 |
Tularik Inc. |
Inhibitors of STAT function
|
AUPP609198A0
(en)
|
1998-09-22 |
1998-10-15 |
Curtin University Of Technology |
Use of non-peptidyl compounds for the treatment of insulin related ailments
|
EP1035115B1
(en)
|
1999-02-24 |
2004-09-29 |
F. Hoffmann-La Roche Ag |
4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
|
ATE329920T1
(de)
|
1999-09-10 |
2006-07-15 |
Novo Nordisk As |
Modulatoren der protein tyrosin phosphatase (ptpases)
|
WO2001019831A1
(en)
|
1999-09-10 |
2001-03-22 |
Novo Nordisk A/S |
MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
|
AUPQ288499A0
(en)
|
1999-09-16 |
1999-10-07 |
Biota Scientific Management Pty Ltd |
Antiviral agents
|
US6514964B1
(en)
|
1999-09-27 |
2003-02-04 |
Amgen Inc. |
Fused cycloheptane and fused azacycloheptane compounds and their methods of use
|
IT1315267B1
(it)
|
1999-12-23 |
2003-02-03 |
Novuspharma Spa |
Derivati di 2-(1h-indol-3-il)-2-oxo-acetammidi ad attivita'antitumorale
|
TWI284639B
(en)
|
2000-01-24 |
2007-08-01 |
Shionogi & Co |
A compound having thrombopoietin receptor agonistic effect
|
DE10038019A1
(de)
*
|
2000-08-04 |
2002-02-14 |
Bayer Ag |
Substituierte Triazolopyrid(az)ine
|
US6777400B2
(en)
|
2000-08-05 |
2004-08-17 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative compositions
|
US6562989B2
(en)
*
|
2000-08-07 |
2003-05-13 |
Yale University |
Catalyst for aromatic C—O, C—N, and C—C bond formation
|
TWI259180B
(en)
|
2000-08-08 |
2006-08-01 |
Hoffmann La Roche |
4-Phenyl-pyridine derivatives
|
AR030357A1
(es)
|
2000-08-18 |
2003-08-20 |
Lundbeck & Co As H |
Derivados 4 -, 5 -, 6 - y 7-indol
|
US6550895B1
(en)
|
2000-10-20 |
2003-04-22 |
Silverbrook Research Pty Ltd |
Moving nozzle ink jet with inlet restriction
|
DE60134679D1
(de)
|
2000-10-20 |
2008-08-14 |
Eisai R&D Man Co Ltd |
Stickstoff enthaltende aromatische Heterozyklen
|
EP1217000A1
(en)
|
2000-12-23 |
2002-06-26 |
Aventis Pharma Deutschland GmbH |
Inhibitors of factor Xa and factor VIIa
|
GB0102109D0
(en)
|
2001-01-26 |
2001-03-14 |
Syngenta Ltd |
Chemical process
|
US20100074949A1
(en)
|
2008-08-13 |
2010-03-25 |
William Rowe |
Pharmaceutical composition and administration thereof
|
EP1383799A4
(en)
|
2001-04-10 |
2008-08-06 |
Transtech Pharma Inc |
PROBES, SYSTEMS AND METHODS FOR DISCOVERING MEDICAMENTS
|
JP4535680B2
(ja)
|
2001-04-16 |
2010-09-01 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
新規1h−インダゾール化合物
|
NZ528752A
(en)
|
2001-06-28 |
2006-06-30 |
Pfizer Prod Inc |
Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (MTP) and/or apolipoprotein B (APO B) secretion
|
WO2003007945A1
(en)
|
2001-07-20 |
2003-01-30 |
Boehringer Ingelheim (Canada) Ltd. |
Viral polymerase inhibitors
|
AUPR738301A0
(en)
|
2001-08-30 |
2001-09-20 |
Starpharma Limited |
Chemotherapeutic agents
|
JP4343690B2
(ja)
|
2001-11-13 |
2009-10-14 |
メルク フロスト カナダ リミテツド |
プロテアーゼ阻害薬としてのシアノアルキルアミノ誘導体
|
CZ2004747A3
(cs)
|
2001-12-21 |
2004-11-10 |
Novo Nordisk A/S |
Deriváty amidů jako GK aktivátory
|
US7074805B2
(en)
|
2002-02-20 |
2006-07-11 |
Abbott Laboratories |
Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
|
US20030158188A1
(en)
|
2002-02-20 |
2003-08-21 |
Chih-Hung Lee |
Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
|
AU2003228744A1
(en)
|
2002-04-29 |
2003-11-17 |
The Ohio State University |
Inhibition of protein tyrosine phosphatases and sh2 domains by a neutral phosphotyrosine mimetic
|
MXPA05000130A
(es)
|
2002-06-27 |
2005-02-17 |
Novo Nordisk As |
Derivados de aril-carbonilo como agentes terapeuticos.
|
WO2004007472A1
(ja)
|
2002-07-10 |
2004-01-22 |
Ono Pharmaceutical Co., Ltd. |
Ccr4アンタゴニストおよびその医薬用途
|
TWI244393B
(en)
|
2002-08-06 |
2005-12-01 |
Idenix Pharmaceuticals Inc |
Crystalline and amorphous forms of beta-L-2'-deoxythymidine
|
RU2005111225A
(ru)
|
2002-09-18 |
2005-08-27 |
Оно Фармасьютикал Ко., Лтд. (Jp) |
Производные триазаспиро[5.5]ундекана и лекарственные средства, содержащие их в качестве активного ингредиента
|
MXPA05003366A
(es)
|
2002-09-30 |
2005-10-05 |
Univ California |
Inhibidores de la proteina reguladora de conductancia transmembranal de la fibrosis quistica y usos de los mismos.
|
JP2004131393A
(ja)
|
2002-10-08 |
2004-04-30 |
Kowa Co |
易溶出性製剤
|
US20050215614A1
(en)
|
2002-10-15 |
2005-09-29 |
Rigel Pharmaceuticals, Inc. |
Substituted indoles and their use as hcv inhibitors
|
FR2846327B1
(fr)
|
2002-10-25 |
2006-03-24 |
Merck Sante Sas |
Derives de n-benzodioxolyl, n-benzodioxanyl et n-benzodioxepinyl arylcarboxamides utilisables dans le traitement de dyslipidemies et compositions pharmaceutiques les contenant.
|
CA2504044A1
(en)
|
2002-11-01 |
2004-05-21 |
Merck & Co., Inc. |
Carbonylamino-benzimidazole derivatives as androgen receptor modulators
|
DE10251019A1
(de)
|
2002-11-02 |
2004-05-19 |
Aventis Pharma Deutschland Gmbh |
Neue Pyrimidin-4,6-dicarbonsäurediamide zur selektiven Inhibierung von Kollagenasen
|
PL375044A1
(en)
|
2002-11-02 |
2005-11-14 |
Sanofi-Aventis Deutschland Gmbh |
Novel pyrimidine-4,6-dicarboxamides for the selective inhibition of collagenases
|
US20040146941A1
(en)
|
2002-11-04 |
2004-07-29 |
Biliang Zhang |
Chemical encoding technology for combinatorial synthesis
|
WO2004056744A1
(en)
|
2002-12-23 |
2004-07-08 |
Janssen Pharmaceutica N.V. |
Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
|
DE10300017A1
(de)
|
2003-01-03 |
2004-07-15 |
Aventis Pharma Deutschland Gmbh |
Selektive MMP 13 Inhibitoren
|
CA2512582C
(en)
|
2003-01-08 |
2014-07-08 |
University Of Washington |
Antibacterial agents
|
US6933311B2
(en)
|
2003-02-11 |
2005-08-23 |
Abbott Laboratories |
Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
|
ATE450533T1
(de)
|
2003-02-14 |
2009-12-15 |
Glaxo Group Ltd |
Carboxamidderivate
|
DE10306941A1
(de)
|
2003-02-18 |
2004-08-26 |
Merck Patent Gmbh |
Benzofuranoxyethylamine
|
EP1601657A1
(en)
|
2003-03-12 |
2005-12-07 |
Vertex Pharmaceuticals Incorporated |
Pyrazole modulators of atp-binding cassette transporters
|
DE10315377A1
(de)
|
2003-04-03 |
2004-10-14 |
Merck Patent Gmbh |
Carbonylverbindungen
|
WO2004087646A2
(de)
|
2003-04-03 |
2004-10-14 |
Merck Patent Gmbh |
Pyrrolidin -1,2-dicarbonsäure-1-(phenylamid) -2- (4-(3-oxo-morpholin-4-yl)-phenylamid) derivate und verwandte verbindungen als inhibitoren des koagulationsfaktors xa zur behandlung von thromboembolischen erkrankungen
|
US20050164951A1
(en)
|
2003-04-03 |
2005-07-28 |
The Regents Of The University Of California |
Inhibitors for the soluble epoxide hydrolase
|
ATE482747T1
(de)
|
2003-04-11 |
2010-10-15 |
High Point Pharmaceuticals Llc |
Neue amide derivate und deren pharmazeutische verwendungen
|
ES2770035T3
(es)
|
2003-04-11 |
2020-06-30 |
Ptc Therapeutics Inc |
Compuesto de ácido 1,2,4-oxadiazol benzoico y su uso para la supresión sin sentido y el tratamiento de enfermedades
|
WO2004110352A2
(en)
|
2003-05-16 |
2004-12-23 |
The Regents Of The University Of California |
Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
|
EP1646615B1
(en)
|
2003-06-06 |
2009-08-26 |
Vertex Pharmaceuticals Incorporated |
Pyrimidine derivatives as modulators of atp-binding cassette transporters
|
WO2005002519A2
(en)
|
2003-06-27 |
2005-01-13 |
Henry M.Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Amphiphilic pyridinium compounds, method of making and use thereof
|
US20050113576A1
(en)
|
2003-08-05 |
2005-05-26 |
Chih-Hung Lee |
Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
|
MXPA06001738A
(es)
|
2003-08-15 |
2006-05-12 |
Lundbeck & Co As H |
Derivados de ciclopropilo como antagonistas del receptor nk3.
|
KR20060088537A
(ko)
|
2003-09-06 |
2006-08-04 |
버텍스 파마슈티칼스 인코포레이티드 |
Atp-결합 카세트 수송체의 조절자
|
US20050070718A1
(en)
|
2003-09-30 |
2005-03-31 |
Abbott Gmbh & Co. Kg |
Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
|
JP2007509044A
(ja)
|
2003-10-08 |
2007-04-12 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
シクロアルキルピラニル基を含むatp結合カセットトランスポーターのモジュレータ
|
WO2005037802A1
(ja)
*
|
2003-10-16 |
2005-04-28 |
Sankyo Company, Limited |
5-アリールピリミジン誘導体
|
JPWO2005040135A1
(ja)
|
2003-10-24 |
2007-03-08 |
小野薬品工業株式会社 |
抗ストレス薬およびその医薬用途
|
JP4869072B2
(ja)
|
2003-11-14 |
2012-02-01 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Atp結合カセットトランスポーターのモジュレーターとして有用なチアゾールおよびオキサゾール
|
GB0330043D0
(en)
|
2003-12-24 |
2004-01-28 |
Pharmacia Italia Spa |
Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
|
US8759335B2
(en)
|
2004-01-30 |
2014-06-24 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
US7977322B2
(en)
|
2004-08-20 |
2011-07-12 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
CA2553040A1
(en)
|
2004-02-02 |
2005-08-18 |
Ambrx, Inc. |
Modified human four helical bundle polypeptides and their uses
|
WO2005094374A2
(en)
|
2004-03-30 |
2005-10-13 |
The Regents Of The University Of California |
Hydrazide-containing cftr inhibitor compounds and uses thereof
|
US20050222271A1
(en)
|
2004-03-31 |
2005-10-06 |
Le Huang |
Novel amorphous form of memantine hydrochloride
|
FR2868417B1
(fr)
|
2004-04-02 |
2006-06-23 |
Rhodia Chimie Sa |
Procede de formation d'une liaison carbone-carbone
|
CA2568499A1
(en)
|
2004-06-01 |
2005-12-15 |
Tm Bioscience Corporation |
Method of detecting cystic fibrosis associated mutations
|
EP1765347A4
(en)
|
2004-06-04 |
2008-10-01 |
Univ California |
COMPOUNDS WITH ION TRANSPORTER HEALING EFFECT BY MUTANT CFTR AND ITS USE
|
US20140343098A1
(en)
|
2004-06-24 |
2014-11-20 |
Vertex Pharmaceuticals Incorporated |
Modulators of atp-binding cassette transporters
|
US8354427B2
(en)
|
2004-06-24 |
2013-01-15 |
Vertex Pharmaceutical Incorporated |
Modulators of ATP-binding cassette transporters
|
CN101006076B
(zh)
|
2004-06-24 |
2010-09-29 |
沃泰克斯药物股份有限公司 |
Atp-结合弹夹转运蛋白的调控剂
|
CA2572292A1
(en)
|
2004-07-02 |
2006-02-09 |
Advancis Pharmaceutical Corporation |
Tablet for pulsed delivery
|
GB0416730D0
(en)
|
2004-07-27 |
2004-09-01 |
Novartis Ag |
Organic compounds
|
MX2007001215A
(es)
|
2004-08-06 |
2007-04-17 |
Otsuka Pharma Co Ltd |
Compuestos aromaticos.
|
DE102004047254A1
(de)
|
2004-09-29 |
2006-04-13 |
Merck Patent Gmbh |
Carbonylverbindungen
|
CA2583177A1
(en)
|
2004-10-13 |
2006-04-27 |
Ptc Therapeutics, Inc. |
Compounds for nonsense suppression, and methods for their use
|
NZ554555A
(en)
|
2004-10-20 |
2011-09-30 |
Univ California |
Cyclohexyl-urea derivatives as improved inhibitors for the soluble epoxide hydrolase
|
US20080051418A1
(en)
|
2004-11-26 |
2008-02-28 |
Tsuyoshi Maekawa |
Arylalkanoic Acid Derivative
|
NZ560513A
(en)
|
2005-02-25 |
2010-07-30 |
Ono Pharmaceutical Co |
Indole compound and use thereof
|
EP1865949B1
(en)
|
2005-03-11 |
2012-11-14 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
KR20070114820A
(ko)
|
2005-03-18 |
2007-12-04 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
돌연변이-cftr 처리를 보정하는데 활성을 가지는화합물 및 이것의 사용
|
US20100120789A1
(en)
|
2005-03-24 |
2010-05-13 |
Nigel Vicker |
Compound
|
US7402596B2
(en)
|
2005-03-24 |
2008-07-22 |
Renovis, Inc. |
Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
|
GB0506133D0
(en)
|
2005-03-24 |
2005-05-04 |
Sterix Ltd |
Compound
|
EP1864978A4
(en)
|
2005-03-28 |
2009-07-01 |
Toyama Chemical Co Ltd |
PROCESS FOR PRODUCING 1- (3- (2- (1-BENZOTHIOPHEN-5-YL) -ETHOXY) PROPYL) AZETIDIN-3-OL OR ITS SALTS
|
JP2006282534A
(ja)
|
2005-03-31 |
2006-10-19 |
Fuji Photo Film Co Ltd |
アミド類の製造方法
|
NZ562197A
(en)
|
2005-04-08 |
2010-09-30 |
Ptc Therapeutics Inc |
Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
|
US20070032475A1
(en)
|
2005-04-15 |
2007-02-08 |
Ye Xiaocong M |
Novel compounds useful for bradykinin B1 receptor antagonism
|
CA2609392A1
(en)
|
2005-05-24 |
2006-11-30 |
Vertex Pharmaceuticals Incorporated |
Modulators of atp-binding cassette transporters
|
AU2006279810B2
(en)
|
2005-08-11 |
2011-10-27 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
CN101287732A
(zh)
|
2005-08-11 |
2008-10-15 |
沃泰克斯药物股份有限公司 |
囊性纤维化跨膜电导调节剂的调控剂
|
AU2006297414A1
(en)
*
|
2005-09-29 |
2007-04-12 |
Wyeth |
1- (1H- indol- 1-yl) -3- (methylamino) -1- phenylpropan-2-ol derivatives and related compounds as modulators of the monoamine reuptake for the treatment of vasomotor symptoms (VMS)
|
US8314256B2
(en)
|
2005-10-06 |
2012-11-20 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
JP2009514875A
(ja)
|
2005-11-02 |
2009-04-09 |
サイトキネティクス・インコーポレーテッド |
化学物質、組成物、および方法
|
EP2404919B1
(en)
|
2005-11-08 |
2013-08-21 |
Vertex Pharmaceuticals Incorporated |
Heterocyclic compound useful as a modulator of ATP-binding cassette transporters.
|
US20120232059A1
(en)
|
2005-11-08 |
2012-09-13 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette Transporters
|
GB0525144D0
(en)
|
2005-12-09 |
2006-01-18 |
Novartis Ag |
Organic compounds
|
DK1966214T3
(en)
*
|
2005-12-21 |
2017-02-13 |
Janssen Pharmaceutica Nv |
TRIAZOLPYRIDAZINES AS TYROSINKINASA MODULATORS
|
JP2009521468A
(ja)
|
2005-12-24 |
2009-06-04 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Abc輸送体の調節因子としてのキノリン−4−オン誘導体
|
EP1974212A1
(en)
|
2005-12-27 |
2008-10-01 |
Vertex Pharmaceuticals Incorporated |
Compounds useful in cftr assays and methods therewith
|
JP5165586B2
(ja)
|
2005-12-28 |
2013-03-21 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
嚢胞性線維症の処置のためのATP結合カセットトランスポーターのモジュレーターとしての、1−(ベンゾ[d][1,3]ジオキソール−5−イル)−N−(フェニル)シクロプロパン−カルボキサミド誘導体および関連化合物
|
DK3219705T3
(da)
|
2005-12-28 |
2020-04-14 |
Vertex Pharma |
Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
|
US7671221B2
(en)
|
2005-12-28 |
2010-03-02 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
TW200808723A
(en)
|
2006-03-13 |
2008-02-16 |
Univ California |
Conformationally restricted urea inhibitors of soluble epoxide hydrolase
|
RS20090406A
(en)
|
2006-03-20 |
2010-12-31 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions
|
EP2001498A4
(en)
|
2006-03-20 |
2013-01-23 |
Vertex Pharma |
PHARMACEUTICAL COMPOSITIONS
|
WO2007111994A2
(en)
|
2006-03-22 |
2007-10-04 |
Syndexa Pharmaceuticals Corporation |
Compounds and methods for treatment of disorders associated with er stress
|
US10022352B2
(en)
|
2006-04-07 |
2018-07-17 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
US7645789B2
(en)
|
2006-04-07 |
2010-01-12 |
Vertex Pharmaceuticals Incorporated |
Indole derivatives as CFTR modulators
|
ATE534383T1
(de)
|
2006-05-12 |
2011-12-15 |
Vertex Pharma |
Zusammensetzungen aus n-ä2,4-bis(1,1- dimethylethyl)-5-hydroxyphenylü-1,4-dihydro-4- oxochinolin-3-carboxamid
|
WO2007146712A2
(en)
|
2006-06-09 |
2007-12-21 |
Kemia, Inc. |
Therapy using cytokine inhibitors
|
WO2008020227A2
(en)
|
2006-08-17 |
2008-02-21 |
Astrazeneca Ab |
Antibacterial pyrrolecarboxamides
|
WO2008029168A2
(en)
|
2006-09-08 |
2008-03-13 |
Summit Corporation Plc |
Treatment of duchenne muscular dystrophy
|
WO2008029152A2
(en)
|
2006-09-08 |
2008-03-13 |
Summit Corporation Plc |
Treatment of duchenne muscular dystrophy
|
BRPI0717317A2
(pt)
*
|
2006-10-23 |
2013-10-22 |
Sgx Pharmaceuticals Inc |
Modularoes da proteína cinase triazalopiridazina
|
US8563573B2
(en)
|
2007-11-02 |
2013-10-22 |
Vertex Pharmaceuticals Incorporated |
Azaindole derivatives as CFTR modulators
|
CN103159760B
(zh)
|
2006-11-03 |
2016-06-08 |
沃泰克斯药物股份有限公司 |
作为cftr调控剂的氮杂吲哚衍生物
|
US7754739B2
(en)
|
2007-05-09 |
2010-07-13 |
Vertex Pharmaceuticals Incorporated |
Modulators of CFTR
|
US20080132560A1
(en)
|
2006-11-21 |
2008-06-05 |
San-Laung Chow |
Solid dispersion composition
|
WO2008065732A1
(fr)
|
2006-11-27 |
2008-06-05 |
Nippon Polyurethane Industry Co., Ltd. |
Procédé de production d'un mélange à base d'isocyanate modifié contenant une liaison allophanate et une liaison isocyanurate
|
US20080260820A1
(en)
|
2007-04-19 |
2008-10-23 |
Gilles Borrelly |
Oral dosage formulations of protease-resistant polypeptides
|
US8969386B2
(en)
|
2007-05-09 |
2015-03-03 |
Vertex Pharmaceuticals Incorporated |
Modulators of CFTR
|
CN101687883B
(zh)
|
2007-05-25 |
2012-05-23 |
沃泰克斯药物股份有限公司 |
囊性纤维化跨膜传导调节因子的调节剂
|
US8557823B2
(en)
|
2007-06-18 |
2013-10-15 |
Advanced Cancer Therapeutics, Llc |
Family of PFKFB3 inhibitors with anti-neoplastic activities
|
WO2008156783A2
(en)
|
2007-06-18 |
2008-12-24 |
University Of Louisville Research Foundation, Inc. |
Family of pfkfb3 inhibitors with anti-neoplastic activities
|
ES2551095T3
(es)
|
2007-07-19 |
2015-11-16 |
Lundbeck, H., A/S |
Amidas heterocíclicas de 5 miembros y compuestos relacionados
|
US20110177999A1
(en)
|
2007-08-09 |
2011-07-21 |
Vertex Pharmaceuticals Incorporated |
Therapeutic Combinations Useful in Treating CFTR Related Diseases
|
WO2009038913A2
(en)
|
2007-08-24 |
2009-03-26 |
Vertex Pharmaceuticals Incorporated |
Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis
|
JP5461405B2
(ja)
|
2007-09-14 |
2014-04-02 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
嚢胞性線維症膜コンダクタンス制御因子の調節因子
|
NZ583848A
(en)
|
2007-09-14 |
2012-07-27 |
Vertex Pharma |
Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
WO2009055917A1
(en)
|
2007-11-02 |
2009-05-07 |
Methylgene Inc. |
Inhibitors of histone deacetylase
|
EP2217572B1
(en)
|
2007-11-16 |
2013-11-06 |
Vertex Pharmaceuticals Incorporated |
Isoquinoline modulators of atp-binding cassette transporters
|
EP2218718A1
(en)
|
2007-11-22 |
2010-08-18 |
Zenyaku Kogyo Kabushikikaisha |
Amorphous form of heterocyclic compound, solid dispersion and medicinal preparation each comprising the same, and process for production of the same
|
PL2225230T3
(pl)
|
2007-12-07 |
2017-08-31 |
Vertex Pharmaceuticals Incorporated |
Stałe postacie kwasu 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-ilo)cyklopropanokarboksyamido)-3-metylopirydyn-2-ylo)benzoesowego
|
MX364936B
(es)
|
2007-12-07 |
2019-05-15 |
Vertex Pharma |
Procesos para producir acidos cicloalquilcarboxamido-piridin benzoicos.
|
US20100036130A1
(en)
|
2007-12-07 |
2010-02-11 |
Vertex Pharmaceuticals Incorporated |
Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
|
EP2237768A2
(en)
|
2007-12-07 |
2010-10-13 |
Vertex Pharmaceuticals Incorporated |
Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
|
EP2231671B1
(en)
|
2007-12-13 |
2013-04-24 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
US20090247521A1
(en)
|
2007-12-28 |
2009-10-01 |
Arete Therapeutics, Inc. |
Soluble epoxide hydrolase inhibitors for the treatment of endothelial dysfunction
|
ES2647531T3
(es)
|
2008-02-28 |
2017-12-22 |
Vertex Pharmaceuticals Incorporated |
Derivados de heteroarilo como moduladores de CFTR
|
EP2271621B1
(en)
|
2008-03-31 |
2013-11-20 |
Vertex Pharmaceuticals Incorporated |
Pyridyl derivatives as cftr modulators
|
US20110071197A1
(en)
|
2008-04-16 |
2011-03-24 |
Peter Nilsson |
Bis-aryl compounds for use as medicaments
|
WO2009129501A1
(en)
|
2008-04-18 |
2009-10-22 |
Arete Therapeutics, Inc. |
Use of soluble epoxide hydrolase inhibitors in the treatment of smooth muscle disorders
|
PT2276485E
(pt)
|
2008-04-24 |
2014-10-20 |
Bristol Myers Squibb Co |
Utilização de epotilona d no tratamento de doenças tauassociadas que compreendem a doença de alzheimer
|
US20110112193A1
(en)
|
2008-05-14 |
2011-05-12 |
Peter Nilsson |
Bis-aryl compounds for use as medicaments
|
US9447049B2
(en)
|
2010-03-01 |
2016-09-20 |
University Of Tennessee Research Foundation |
Compounds for treatment of cancer
|
US8822513B2
(en)
|
2010-03-01 |
2014-09-02 |
Gtx, Inc. |
Compounds for treatment of cancer
|
US20100256184A1
(en)
|
2008-08-13 |
2010-10-07 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition and administrations thereof
|
CA2733908C
(en)
|
2008-08-13 |
2017-05-30 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition comprising a solid dispersion of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
US8895781B2
(en)
|
2008-09-04 |
2014-11-25 |
Georgetown University |
Transition metal-catalyzed C—H amination using unactivated amines
|
AR073578A1
(es)
|
2008-09-15 |
2010-11-17 |
Priaxon Ag |
Pirrolidin-2-onas
|
AR073709A1
(es)
|
2008-09-29 |
2010-11-24 |
Vertex Pharma |
Unidades de dosis de acido 3-(6-(1-(2,2-difluorobenzeno (d) (1,3) dioxol-5-il) ciclopropancarboxamido)-3-metilpiridin-2-il) benzoico
|
WO2010048149A2
(en)
|
2008-10-20 |
2010-04-29 |
Kalypsys, Inc. |
Heterocyclic modulators of gpr119 for treatment of disease
|
US20110257223A1
(en)
*
|
2008-10-23 |
2011-10-20 |
Vertex Pharmaceuticals Incorporated |
Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
|
ES2532138T3
(es)
|
2008-10-23 |
2015-03-24 |
Vertex Pharmaceuticals Incorporated |
Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
|
TWI465449B
(zh)
*
|
2008-10-23 |
2014-12-21 |
Vertex Pharma |
囊腫性纖維化跨膜傳導調節因子之調控因子
|
EP2358680B1
(en)
|
2008-10-23 |
2013-03-20 |
Vertex Pharmaceuticals Incorporated |
Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide
|
UA104876C2
(uk)
|
2008-11-06 |
2014-03-25 |
Вертекс Фармасьютікалз Інкорпорейтед |
Модулятори atф-зв'язувальних касетних транспортерів
|
ES2532753T3
(es)
|
2008-11-06 |
2015-03-31 |
Vertex Pharmaceuticals Incorporated |
Moduladores de transportadores del casete de unión a ATP
|
CA2743241A1
(en)
|
2008-11-27 |
2010-06-03 |
Boehringer Ingelheim International Gmbh |
6,7,8,9-tetrahydro-5h-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
|
BRPI0922364A2
(pt)
|
2008-12-03 |
2017-08-29 |
Presidio Pharmaceuticals Inc |
Composto, composição farmacêutica e uso de um composto
|
US8367660B2
(en)
|
2008-12-30 |
2013-02-05 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
US8946419B2
(en)
|
2009-02-23 |
2015-02-03 |
Mallinckrodt Llc |
(+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives
|
WO2010104307A2
(ko)
|
2009-03-07 |
2010-09-16 |
주식회사 메디젠텍 |
세포핵에서 세포질로의 gsk3의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
|
AU2010226393B2
(en)
|
2009-03-20 |
2016-08-11 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
PT2408750E
(pt)
|
2009-03-20 |
2015-10-15 |
Vertex Pharma |
Processo para a produção de modeladores do regulador de condutância transmembranar da fibrose cística
|
GB0905641D0
(en)
|
2009-04-01 |
2009-05-13 |
Serodus As |
Compounds
|
DK2419429T3
(da)
|
2009-04-16 |
2014-06-23 |
Ct Nac De Investigaciones Oncológicas Cnio |
Imidazopyraziner som inhibitorer af proteinkinaser
|
WO2011005355A1
(en)
|
2009-05-07 |
2011-01-13 |
Achaogen, Inc. |
Combinations comprising a lpxc inhibitor and an antibiotic for use in the treatment of infections caused by gram-negative bacteria
|
CN105254557A
(zh)
|
2009-05-29 |
2016-01-20 |
拉夸里亚创药株式会社 |
作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物
|
EP2264012A1
(de)
|
2009-06-03 |
2010-12-22 |
Bayer CropScience AG |
Heteroarylamidine und deren Verwendung als Fungizide
|
KR101256018B1
(ko)
|
2009-08-20 |
2013-04-18 |
한국과학기술연구원 |
단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
|
WO2011029832A1
(de)
|
2009-09-09 |
2011-03-17 |
Vifor (International) Ag |
Neue thiazol- und oxazol-hepcidin-antagonisten
|
CN102498112B
(zh)
|
2009-09-17 |
2015-05-20 |
沃泰克斯药物股份有限公司 |
制备氮杂二环化合物的方法
|
US9334230B2
(en)
|
2009-09-18 |
2016-05-10 |
Nanyang Technological University |
Process of forming an amide
|
EP2490687A1
(en)
|
2009-10-22 |
2012-08-29 |
Vertex Pharmaceuticals Incorporated |
Compositions for treatment of cystic fibrosis and other chronic diseases
|
BR112012009583A2
(pt)
|
2009-10-23 |
2015-09-29 |
Vertex Pharma |
processo para preparação de moduladores de regulador de condutância de transmembrana de fibrose cística
|
MX2012004791A
(es)
|
2009-10-23 |
2013-02-01 |
Vertex Pharma |
Formas sólidas de n-(4-(7-azabiciclo[2.2.1]heptan-7-il)-2-(trifluo rometil)fenil)-4-oxo-5-(trifluorometil)-1,4-dihidroquinolina-3-ca rboxamida.
|
WO2011094890A1
(en)
|
2010-02-02 |
2011-08-11 |
Argusina Inc. |
Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
|
RU2581367C2
(ru)
|
2010-03-01 |
2016-04-20 |
Джи Ти Икс, ИНК. |
Соединения для лечения рака
|
WO2011115892A1
(en)
|
2010-03-15 |
2011-09-22 |
Griffin Patrick R |
Modulators of the retinoic acid receptor-related orphan receptors
|
EP3037415A1
(en)
|
2010-03-19 |
2016-06-29 |
Vertex Pharmaceuticals Inc. |
Solid form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
US8802868B2
(en)
*
|
2010-03-25 |
2014-08-12 |
Vertex Pharmaceuticals Incorporated |
Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
|
RS61314B1
(sr)
*
|
2010-03-25 |
2021-02-26 |
Vertex Pharma |
Čvrsta disperzija amorfnog oblika (r)-1(2,2-difluorobenzo(d)(1,3)dioksol-5-il)-n-(1-(2,3-dihidroksipropil)-6-fluoro-2-(1-hidroksi-2-metilpropan-2-il)-1h-indol-5-il)-ciklopropankarboksamida
|
RS54783B1
(sr)
|
2010-04-07 |
2016-10-31 |
Vertex Pharma |
Čvrste forme 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksiamido)-3-metilpiridin-2-il)benzoeve kiseline
|
NZ602838A
(en)
|
2010-04-07 |
2015-06-26 |
Vertex Pharma |
Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid and administration thereof
|
WO2011133951A1
(en)
|
2010-04-22 |
2011-10-27 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions and administrations thereof
|
SG184987A1
(en)
*
|
2010-04-22 |
2012-11-29 |
Vertex Pharma |
Process of producing cycloalkylcarboxamido-indole compounds
|
CA2796602A1
(en)
*
|
2010-04-22 |
2011-10-27 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions and administrations thereof
|
NZ603044A
(en)
*
|
2010-04-22 |
2015-08-28 |
Vertex Pharma |
Pharmaceutical compositions comprising cftr modulators and administrations thereof
|
EP2386606B1
(fr)
|
2010-04-30 |
2018-03-21 |
Total Marketing Services |
Utilisation de dérivés organogelateurs dans des compositions bitumineuses pour améliorer leur résistance aux agressions chimiques
|
EP2571506B1
(en)
|
2010-05-20 |
2017-05-10 |
Cempra Pharmaceuticals, Inc. |
Processes for preparing macrolides and ketolides and intermediates therefor
|
WO2011146886A1
(en)
|
2010-05-20 |
2011-11-24 |
Vertex Pharmaceuticals Incorporated |
Processes for producing modulators of cystic fibrosis transmembrane conductance regulator
|
CA2798412A1
(en)
|
2010-05-20 |
2011-11-24 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions and administrations thereof
|
US8563593B2
(en)
*
|
2010-06-08 |
2013-10-22 |
Vertex Pharmaceuticals Incorporated |
Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
|
US20120149708A1
(en)
|
2010-06-17 |
2012-06-14 |
George Mason University |
Modulators of viral transcription, and methods and compositions therewith
|
UA110113C2
(xx)
|
2010-07-29 |
2015-11-25 |
|
Біциклічні азагетероциклічні карбоксаміди
|
WO2012016133A2
(en)
|
2010-07-29 |
2012-02-02 |
President And Fellows Of Harvard College |
Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
|
CA2808501A1
(en)
*
|
2010-08-23 |
2012-03-01 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof
|
MX2013002353A
(es)
|
2010-08-27 |
2013-09-26 |
Vertex Pharma |
Composicion farmaceutica y administraciones de la misma.
|
WO2012049555A1
(en)
|
2010-10-13 |
2012-04-19 |
Lupin Limited |
Spirocyclic compounds as voltage-gated sodium channel modulators
|
WO2012052540A1
(en)
|
2010-10-21 |
2012-04-26 |
Universitaet Des Saarlandes |
Selective cyp11b1 inhibitors for the treatment of cortisol dependent diseases
|
US8802700B2
(en)
|
2010-12-10 |
2014-08-12 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
WO2012079583A1
(en)
|
2010-12-15 |
2012-06-21 |
Aarhus Universitet |
System providing controlled delivery of gaseous co for carbonylation reactions
|
CA2827392A1
(en)
|
2011-02-24 |
2012-08-30 |
Emory University |
Noggin blocking compositions for ossification and methods related thereto
|
WO2012129562A2
(en)
|
2011-03-24 |
2012-09-27 |
The Scripps Research Institute |
Compounds and methods for inducing chondrogenesis
|
CN102731492B
(zh)
|
2011-03-30 |
2016-06-29 |
江苏恒瑞医药股份有限公司 |
环己烷类衍生物、其制备方法及其在医药上的应用
|
HUE047354T2
(hu)
|
2011-05-18 |
2020-04-28 |
Vertex Pharmaceuticals Europe Ltd |
Ivacaftor deuterizált származékai
|
US8945605B2
(en)
|
2011-06-07 |
2015-02-03 |
Parion Sciences, Inc. |
Aerosol delivery systems, compositions and methods
|
WO2013005057A1
(en)
|
2011-07-07 |
2013-01-10 |
Centro Nacional De Investigaciones Oncológicas (Cnio) |
New compounds
|
BR112014005286B1
(pt)
|
2011-09-09 |
2022-08-23 |
Lantheus Medical Imaging, Inc |
Compostos de um primeiro e um segundo agente de imageamento para determinar incompatibilidade de inervação e perfusão na parte do indivíduo
|
WO2013038373A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
WO2013038381A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine/pyrazine amide derivatives
|
WO2013038386A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Heterocyclic compounds for the treatment of cystic fibrosis
|
JP6165733B2
(ja)
|
2011-09-16 |
2017-07-19 |
ノバルティス アーゲー |
N−置換ヘテロシクリルカルボキサミド類
|
WO2013038378A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
GB201116559D0
(en)
|
2011-09-26 |
2011-11-09 |
Univ Leuven Kath |
Novel viral replication inhibitors
|
CA2853299A1
(en)
|
2011-11-02 |
2013-05-10 |
Vertex Pharmaceuticals Incorporated |
Use of (n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide) for treating cftr mediated diseases
|
MX357328B
(es)
*
|
2011-11-08 |
2018-07-05 |
Vertex Pharma |
Moduladores de trasportadores de casete enlazante de atp.
|
US20140127901A1
(en)
*
|
2012-11-08 |
2014-05-08 |
Taiwan Semiconductor Manufacturing Company, Ltd. |
Low-k damage free integration scheme for copper interconnects
|
WO2013086131A1
(en)
|
2011-12-06 |
2013-06-13 |
The Trustees Of The University Of Pennsylvania |
Inhibitors targeting drug-resistant influenza a
|
US8772541B2
(en)
|
2011-12-15 |
2014-07-08 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Cannabinoid receptor 2 (CB2) inverse agonists and therapeutic potential for multiple myeloma and osteoporosis bone diseases
|
EP2606726A1
(de)
|
2011-12-21 |
2013-06-26 |
Bayer CropScience AG |
N-Arylamidine-substituierte trifluoroethylsulfid-Derivate als Akarizide und Insektizide
|
KR20140117612A
(ko)
|
2012-01-25 |
2014-10-07 |
버텍스 파마슈티칼스 인코포레이티드 |
3-(6-(1-(2,2-다이플루오로벤조[d][1,3]다이옥솔-5-일) 사이클로프로판카르복사미도)-3-메틸피리딘-2-일)벤조산의 제형
|
EP2819670A1
(en)
|
2012-02-27 |
2015-01-07 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition and administration thereof
|
JP2015518504A
(ja)
|
2012-04-03 |
2015-07-02 |
スリーエム イノベイティブ プロパティズ カンパニー |
光塩基発生剤を含む架橋性組成物
|
US8674108B2
(en)
|
2012-04-20 |
2014-03-18 |
Vertex Pharmaceuticals Incorporated |
Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
US9528016B2
(en)
|
2012-04-26 |
2016-12-27 |
Xerox Corporation |
Phase change inks comprising crystalline amides
|
US8888905B2
(en)
|
2012-04-26 |
2014-11-18 |
Xerox Corporation |
Fast crystallizing crystalline-amorphous ink compositions and methods for making the same
|
CA2813472A1
(en)
|
2012-04-26 |
2013-10-26 |
Xerox Corporation |
Rapid solidifying crystalline-amorphous inks
|
US9228101B2
(en)
|
2012-04-26 |
2016-01-05 |
Xerox Corporation |
Rapidly crystallizing phase change inks and methods for forming the same
|
US20130284054A1
(en)
|
2012-04-26 |
2013-10-31 |
Xerox Corporation |
Rapid solidifying crystalline-amorphous inks
|
GB2502624A
(en)
|
2012-06-01 |
2013-12-04 |
Univ East Anglia |
Phosphoramide and phosphoramide-based catalysts and their use in intermolecular aziridination
|
EP2859005B1
(en)
|
2012-06-08 |
2018-10-31 |
Massachusetts Institute of Technology |
Phosphine-ligated palladium sulfonate palladacycles
|
AU2013270681A1
(en)
*
|
2012-06-08 |
2014-12-18 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions for the treatment of CFTR -mediated disorders
|
FR2992317B1
(fr)
|
2012-06-22 |
2016-05-13 |
Diverchim |
Procede de preparation de peptides chiraux
|
WO2014002106A1
(en)
|
2012-06-25 |
2014-01-03 |
Cadila Healthcare Limited |
Novel compounds for the treatment of dyslipidemia and related diseases
|
NZ703824A
(en)
|
2012-07-12 |
2018-06-29 |
Proqr Therapeutics Ii Bv |
Oligonucleotides for making a change in the sequence of a target rna molecule present in a living cell
|
WO2014011050A1
(en)
|
2012-07-12 |
2014-01-16 |
Proqr Therapeutics B.V. |
Exon replacement with stabilized artificial rnas
|
AU2013290444B2
(en)
|
2012-07-16 |
2018-04-26 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
|
US10207989B2
(en)
|
2012-09-20 |
2019-02-19 |
Temple University—Of the Commonwealth System of Higher Education |
Substituted alkyl diaryl derivatives, methods of preparation and uses
|
WO2014068893A1
(ja)
|
2012-10-29 |
2014-05-08 |
コニカミノルタ株式会社 |
位相差フィルム、円偏光板、及び画像表示装置
|
HRP20181740T4
(hr)
|
2012-11-02 |
2024-01-05 |
Vertex Pharmaceuticals Incorporated |
Farmaceutski pripravci za liječenje bolesti koje su posredovane s cftr
|
US9757379B2
(en)
|
2012-11-14 |
2017-09-12 |
The Board Of Regents Of The University Of Texas System |
Inhibition of HIF-2α heterodimerization with HIF1β (ARNT)
|
JP6146990B2
(ja)
|
2012-11-16 |
2017-06-14 |
コンサート ファーマシューティカルズ インコーポレイテッド |
重水素化されたcftr増強物質
|
SG11201503959VA
(en)
|
2012-11-20 |
2015-06-29 |
Merial Inc |
Anthelmintic compounds and compositions and method of using thereof
|
ITMI20122065A1
(it)
|
2012-12-03 |
2014-06-04 |
Univ Padova |
Uso dei correttori del cftr nel trattamento delle patologie del muscolo striato
|
EP2929346A1
(en)
|
2012-12-05 |
2015-10-14 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Diagnosis of cystic fibrosis
|
US20140158127A1
(en)
|
2012-12-07 |
2014-06-12 |
Parion Sciences, Inc. |
Nasal cannula for delivery of aerosolized medicaments
|
US20140221424A1
(en)
|
2013-01-30 |
2014-08-07 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions for use in the treatment of cystic fibrosis
|
US9452139B2
(en)
|
2013-03-14 |
2016-09-27 |
Novartis Ag |
Respirable agglomerates of porous carrier particles and micronized drug
|
US20140296164A1
(en)
|
2013-03-29 |
2014-10-02 |
Calista Therapeutics, Inc. |
Compositions and methods of use for cell targeted inhibitors of the Cystic Fibrosis transmembrane regulator associated ligand
|
AU2014264936B2
(en)
|
2013-05-07 |
2018-09-27 |
Galapagos Nv |
Novel compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
|
AU2014268477A1
(en)
|
2013-05-24 |
2015-11-12 |
The California Institute For Biomedical Research |
Compounds for treatment of drug resistant and persistent tuberculosis
|
JP2014232188A
(ja)
|
2013-05-29 |
2014-12-11 |
コニカミノルタ株式会社 |
セルロースアシレートフィルム、円偏光板及び画像表示装置
|
AU2014302458A1
(en)
|
2013-06-26 |
2015-12-24 |
Proteostasis Therapeutics, Inc. |
Methods of modulating CFTR activity
|
DK3030568T3
(en)
|
2013-08-08 |
2019-01-07 |
Galapagos Nv |
THIENO [2,3-C] PYRANES AS CFTR MODULATORS
|
US9688990B2
(en)
|
2013-09-12 |
2017-06-27 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Methods and pharmaceutical compositions for treatment of cystic fibrosis
|
JP6564380B2
(ja)
|
2013-09-20 |
2019-08-21 |
ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション |
前立腺癌を治療するための化合物
|
EP3052190A4
(en)
|
2013-10-01 |
2017-07-19 |
New York University |
Amino, amido, and heterocyclic compounds as modulators of rage activity and uses thereof
|
US9700881B2
(en)
|
2013-10-09 |
2017-07-11 |
Emory University |
Heterocyclic coupling catalysts and methods related thereto
|
MX2016006118A
(es)
|
2013-11-12 |
2016-07-21 |
Vertex Pharma |
Proceso para preparar composiciones farmaceuticas para el tratamiento de enfermedades mediadas por regulador de la conductancia transmembrana de la fibrosis quistica (cftr).
|
KR20150062652A
(ko)
|
2013-11-29 |
2015-06-08 |
삼성전자주식회사 |
초음파 감응성 리포좀, 그를 포함한 약제학적 조성물 및 그를 이용하여 개체의 체내에 활성제를 전달하는 방법
|
JP6759100B2
(ja)
|
2013-12-30 |
2020-09-23 |
ライフサイ ファーマシューティカルズ,インク. |
治療用阻害化合物
|
US20170029366A1
(en)
|
2014-03-07 |
2017-02-02 |
The Johns Hopkins University |
Inhibitors of histone lysine specific demethylase (lsd1) and histone deacetylases (hdacs)
|
JP2015172005A
(ja)
|
2014-03-11 |
2015-10-01 |
国立大学法人 東京大学 |
鉄触媒によるカップリング化合物の製造方法
|
US9790219B2
(en)
|
2014-03-13 |
2017-10-17 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for increasing CFTR activity
|
WO2015138934A1
(en)
|
2014-03-13 |
2015-09-17 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for increasing cftr activity
|
US10206877B2
(en)
|
2014-04-15 |
2019-02-19 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
|
JP5932881B2
(ja)
*
|
2014-05-08 |
2016-06-08 |
株式会社フジクラ |
マルチコアファイバ及びそのマルチコアファイバの製造方法
|
AU2015255752B2
(en)
|
2014-05-08 |
2020-07-23 |
Immunoforge Co., Ltd. |
Methods and compositions for treating Cystic Fibrosis
|
RU2688191C2
(ru)
|
2014-05-12 |
2019-05-21 |
ВЕРОНА ФАРМА ПиэЛСи |
Новое лечение
|
MY199033A
(en)
|
2014-05-16 |
2023-10-10 |
Olaplex Inc |
Keratin treatment formulations and methods
|
WO2015179414A1
(en)
|
2014-05-19 |
2015-11-26 |
Merial, Inc. |
Anthelmintic compounds
|
AR100724A1
(es)
|
2014-06-05 |
2016-10-26 |
Merck Patent Gmbh |
Derivados de quinolina y su uso en enfermedades neurodegenerativas
|
WO2015196071A1
(en)
|
2014-06-19 |
2015-12-23 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions and methods of increasing cftr activity
|
CN107105749A
(zh)
|
2014-08-13 |
2017-08-29 |
阿克索生物医药公司 |
抗微生物化合物和组合物及其用途
|
GB201415381D0
(en)
|
2014-08-29 |
2014-10-15 |
Algipharma As |
Inhalable powder formulations of alginate oligomers
|
JP2017538659A
(ja)
|
2014-09-10 |
2017-12-28 |
エピザイム インコーポレイテッド |
Smyd阻害剤
|
WO2016050209A1
(zh)
|
2014-10-01 |
2016-04-07 |
厦门赛诺邦格生物科技有限公司 |
一种异官能化聚乙二醇衍生物、制备方法及其生物相关物质
|
WO2016050208A1
(zh)
|
2014-10-01 |
2016-04-07 |
厦门赛诺邦格生物科技有限公司 |
一种多官能化聚乙二醇衍生物修饰的生物相关物质
|
US11324827B2
(en)
|
2014-10-01 |
2022-05-10 |
Xiamen Sinopeg Biotech Co., Ltd. |
Multifunctionalized polyethylene glycol derivative and preparation method therefor
|
CN104725628B
(zh)
|
2014-10-01 |
2018-04-17 |
厦门赛诺邦格生物科技股份有限公司 |
一种含可降解基团的单一官能化支化聚乙二醇、制备方法及其生物相关物质
|
WO2016054560A1
(en)
|
2014-10-02 |
2016-04-07 |
Flatley Discovery Lab |
Isoxazole compounds and methods for the treatment of cystic fibrosis
|
US9573948B2
(en)
|
2014-10-06 |
2017-02-21 |
Flatley Discovery Lab |
Triazolopyridine compounds and methods for the treatment of cystic fibrosis
|
TWI735416B
(zh)
|
2014-10-06 |
2021-08-11 |
美商維泰克斯製藥公司 |
囊腫纖維化症跨膜傳導調節蛋白之調節劑
|
RU2749213C2
(ru)
|
2014-10-07 |
2021-06-07 |
Вертекс Фармасьютикалз Инкорпорейтед |
Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе
|
US20170281612A1
(en)
|
2014-10-08 |
2017-10-05 |
Nivalis Therapeutics, Inc. |
Methods for the Treatment of Cystic Fibrosis
|
US20160108406A1
(en)
|
2014-10-08 |
2016-04-21 |
University Of Iowa Research Foundation |
Method of regulating cftr expression and processing
|
GB201418892D0
(en)
|
2014-10-23 |
2014-12-10 |
Proqr Therapeutics B V |
DNA editing
|
WO2016066582A1
(en)
|
2014-10-28 |
2016-05-06 |
Bci Pharma |
Nucleoside kinase inhibitors
|
EP3212189B1
(en)
|
2014-10-31 |
2020-09-09 |
AbbVie Overseas S.à r.l. |
Substituted chromanes and method of use
|
BR112017009194A2
(pt)
|
2014-10-31 |
2017-12-26 |
Abbvie Sarl |
tetra-hidropiranos substituídos e método de uso
|
WO2016086015A1
(en)
|
2014-11-25 |
2016-06-02 |
University Of Rochester |
Myoglobin-based catalysts for carbene transfer reactions
|
MA41031A
(fr)
|
2014-11-26 |
2017-10-03 |
Catabasis Pharmaceuticals Inc |
Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie
|
WO2016086136A1
(en)
|
2014-11-26 |
2016-06-02 |
Catabasis Pharmaceuticals, Inc. |
Fatty acid cysteamine conjugates of cftr modulators and their use in treating medical disorders
|
US10344023B2
(en)
|
2014-12-23 |
2019-07-09 |
Proteostasis Therapeutics, Inc. |
Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
|
MA41253A
(fr)
|
2014-12-23 |
2017-10-31 |
Proteostasis Therapeutics Inc |
Composés, compositions et procédés pour augmenter l'activité du cftr
|
CA2971850A1
(en)
|
2014-12-23 |
2016-06-30 |
Proteostasis Therapeutics, Inc. |
Derivatives of 5-phenyl- or 5-heteroarylthiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
|
US10738011B2
(en)
|
2014-12-23 |
2020-08-11 |
Proteostasis Therapeutics, Inc. |
Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
|
ES2737227T3
(es)
|
2014-12-24 |
2020-01-10 |
Kither Biotech S R L |
Péptido inhibidor de gamma PI3K novedoso para el tratamiento de enfermedades del sistema respiratorio
|
EP3240539A4
(en)
|
2014-12-31 |
2018-07-25 |
Auspex Pharmaceuticals, Inc. |
Cyclopropanecarboxamide modulators of cystic fibrosis transmembrane conductance regulator
|
WO2016107603A1
(zh)
|
2015-01-01 |
2016-07-07 |
成都贝斯凯瑞生物科技有限公司 |
取代氮杂环衍生物及其应用
|
US20180147187A1
(en)
|
2015-01-12 |
2018-05-31 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for increasing cftr activity
|
CA2981495C
(en)
|
2015-03-31 |
2023-09-26 |
Vertex Pharmaceuticals (Europe) Limited |
Deuterated vx-661
|